Abstract
Several genetic alterations have been associated with sporadic prostate cancer (PCa). In this study, the association between RsaI and DraI polymorphisms of CYP2E1 and PCa risk was analysed in a case-control study of 227 individuals using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Regarding DraI polymorphisms, the DD genotype is over-represented in PCa cases when compared with the control group (odds ratio (OR) 2.12; 95% confidence interval (CI) 1.11-4.05; P=0.022). Regarding the RsaI polymorphism, no significant differences were found. The results of this study indicate that DraI polymorphisms of the CYP2E1 gene may be associated with a twofold increased risk for the development of PCa.
Publication types
-
Comparative Study
-
Evaluation Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Alleles
-
Biomarkers, Tumor / blood
-
Case-Control Studies
-
Cytochrome P-450 CYP2E1 / genetics*
-
Gene Frequency / genetics
-
Genetic Markers / genetics
-
Genetic Predisposition to Disease / epidemiology
-
Genetic Predisposition to Disease / genetics*
-
Genotype
-
Humans
-
Male
-
Middle Aged
-
Polymerase Chain Reaction
-
Polymorphism, Restriction Fragment Length*
-
Portugal / epidemiology
-
Prostate-Specific Antigen / blood
-
Prostatic Neoplasms / epidemiology
-
Prostatic Neoplasms / genetics*
-
Prostatic Neoplasms / metabolism
-
Racial Groups / genetics
-
Risk Factors
-
Statistics as Topic
Substances
-
Biomarkers, Tumor
-
Genetic Markers
-
Cytochrome P-450 CYP2E1
-
Prostate-Specific Antigen